Celgene (NASDAQ:CELG) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Saturday.

CELG has been the subject of several other reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $162.00 price objective on shares of Celgene in a report on Tuesday, September 26th. Vetr raised Celgene from a “hold” rating to a “buy” rating and set a $146.58 price objective for the company in a report on Friday, October 6th. Royal Bank of Canada reaffirmed a “buy” rating and set a $173.00 price objective on shares of Celgene in a report on Thursday, October 5th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Celgene in a report on Monday, October 16th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $160.00 price objective on shares of Celgene in a report on Monday, October 16th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Celgene currently has an average rating of “Buy” and an average price target of $129.98.

Celgene (CELG) traded up $0.93 on Friday, hitting $102.65. The stock had a trading volume of 8,098,686 shares, compared to its average volume of 6,610,000. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The firm has a market cap of $81,560.00, a PE ratio of 24.21, a P/E/G ratio of 0.65 and a beta of 1.77. Celgene has a 1-year low of $94.55 and a 1-year high of $147.17.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the firm earned $1.58 EPS. sell-side analysts expect that Celgene will post 6.7 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in CELG. Winslow Evans & Crocker Inc. raised its stake in Celgene by 25.6% during the fourth quarter. Winslow Evans & Crocker Inc. now owns 11,780 shares of the biopharmaceutical company’s stock valued at $1,229,000 after buying an additional 2,404 shares in the last quarter. Ingalls & Snyder LLC raised its stake in Celgene by 112.0% during the fourth quarter. Ingalls & Snyder LLC now owns 57,231 shares of the biopharmaceutical company’s stock valued at $5,973,000 after buying an additional 30,230 shares in the last quarter. TRUE Private Wealth Advisors acquired a new stake in Celgene during the fourth quarter valued at approximately $241,000. State of Alaska Department of Revenue raised its stake in Celgene by 1,777.2% during the fourth quarter. State of Alaska Department of Revenue now owns 80,437 shares of the biopharmaceutical company’s stock valued at $8,393,000 after buying an additional 76,152 shares in the last quarter. Finally, Syntal Capital Partners LLC acquired a new stake in Celgene during the fourth quarter valued at approximately $407,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/20/bidaskclub-lowers-celgene-celg-to-sell.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.